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A B S TR A C T
O bjective : The aim of the study was to analyse 
the survival results in patients with brain 
métastasés treated by whole brain external 
radiotherapy and determine the prognostic 
factors affecting survival.
M ethods: Eighty-three patients with brain 
métastasés were treated by external 
radiotherapy. Before irradiation 21 had 
metastatectomy, 4 had stereotactic radiosurgery 
and 4 had stereotactic biopsy for diagnosis. The 
primary tumor was controlled in 39 patients 
(47%), 30 (36%) had métastasés other than 
brain. Whole cranial irradiation was performed on 
all patients by a linear accelerator with 6 MV 
energy.
R e su lts : Median follow-up for all patients was 14 
weeks (1-143 weeks). Median overall survival 
and 1 year survival for the whole group was 14 
weeks and 25%, respectively. Cranial 
progression free survival was median 40 weeks. 
In multivariate analysis Karnofsky Performance 
Scale score, gender and metastatectomy / 
radiosurgery were found to be independent 
prognostic factors.
C o n c lu s io n : External radiotherapy is an efficient 
treatment modality for palliation and stabilizing 
cranial progression in patients with brain 
métastasés. Better survival results are obtained
in younger, solitary metastatic patients with good 
performance status and controlled systemic 
disease when metastatectomy or radiosurgery 
added.
K e y  W o rd s : Brain métastasés, Radiotherapy, 
Prognostic factors.
IN T R O D U C T IO N
Brain métastasés occur in approximately 30% of 
cancer patients and represent the most common 
type of intracranial tumors (1). They exert a 
profound effect on the quality and length of life 
and directly cause death in 1/3 to 1/2 of the 
patients (2). Lung (especially small cell, adeno 
types), breast, melanoma and colorectal cancers 
have a propensity to metastasize in the brain 
more frequenlty though it may happen in any type 
of cancer (3). About half of the patients present 
with single lesion (4). Although these patients 
have poor prognosis for long-term survival, 
treatment is mandatory for immediate palliation 
of cranial symptoms and durable symptom-free 
remission. Median survival of symptomatic 
patients with brain métastasés is 1 month without 
any treatment, 2 months with steroid treatment
(5). Whole brain irradiation prolongs survival to 3- 
5 months and achieves palliation of symptoms for 
a longer period with moderate doses like 30 
Gy/10 fractions (2, 6). Occasionally in patients
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with single cerebellar or large cavitatlng cerebral 
lesions who need urgent palliation surgical 
removal is a favourite option prior to radiation 
treatment (7). Recent literature supports 
radiosurgery as an alternative treatment to 
surgery In selected patients (8).
In order to compute survival results with whole 
brain irradiation and to identify prognostic factors 
affecting survival, we performed a retrospective 
analysis.
M A TE R IA L S  A N D  M E T H O D S
Eighty-three patients with diagnosis of brain 
metastases who applied to our department for 
palliative radiotherapy were evaluated 
retrospectively. Characteristics of the patients 
are seen on Table I. Before radiotherapy 19 
cases had a metastatectomy operation, 2 had 
gammaknife radiosurgery and 4 had a 
stereotactic biopsy for diagnosis. Furthermore, 
two patients had both metastatectomy and 
radiosurgery.
The primary tumor was controlled in 39 (47%) of 
the patients after diagnosis of brain metastases. 
Thirty patients (36%) had distant metastases 
other than brain.
All patients were irradiated by a linear accelerator 
with 6 MV energy. Radiation was given with two 
parallel opposed beams covering the whole 
brain. Median total dose to whole brain was 30 
Gy (5-33 Gy). Seven of them were boosted to a 
smaller volume with median 6 Gy (6-15 Gy). 
Overall and progression free survival curves 
were drawn by Kaplan-Meier estimates (9). 
Overall survival was calculated from the start of 
radiotherapy to death of any reason and cranial 
progression for symptomatic or radiological 
progression in the cranium. Univariate analysis 
was performed for age, gender, primary tumor 
type, Karnofsky Performance Scale (KPS) score, 
multiplicity, presence of other distant metastases 
and presence of metastatectomy/radiosurgery 
(M/RS) by log-rank test. Independent prognostic 
factors were identified by Cox regression 
analysis using the significant factors in univariate 
analysis (10).
Table  I. Characteristics of the patients.
number {%)
Male 59 (71.1%)
Female 24 (28.9%)
Age median 57 (35-82 range)
>57 46 (55.4%)
<57 37 (44.6%)
Primary origin
Lung 40 (48.2%)
Breast 11 (13.3%)
Primary unknown 22 (26.5%)
Others 10 (12.0%)
Solitary metastases 19 (22.9%)
Multiple metastases 64 (77.1%)
Karnofsky Performance Scale
score
80-100 57 (68.7%)
50-70 23 (27.7%)
30-40 3 (3.6%)
R ESULTS
Median follow-up for all patients was 14 weeks 
(1-143 weeks). At the time of analysis 59 out of 
83 patients were dead related to their disease 
while 2 patients had died because of intercurrent 
events. Median overall survival and 1 year 
survival for the whole group was 14 weeks and 
25%, respectively (Fig. 1). Progression free 
survival median was 40 weeks (Fig. 2).
In 23 patients with M/RS median survival was 65 
weeks while in 60 patients with only radiotherapy 
it was 12 weeks (p<0.001) (Fig. 3). Patients with 
solitary and multiple metastatic lesions had a 
median survival of 62 weeks and 12 weeks, 
respectively (p=0.006) (Fig. 4).
Other prognostic factors found to be significant 
for survival In univariate analysis were KPS 
score, distant metastases other than brain and 
age (Figs. 5, 6, 7). Male gender showed a trend 
for worse prognosis (Fig. 8). Primary tumor type 
did not influence outcome (p>0.05). Statistically 
significant prognostic factors in univariate 
analysis were entered in multivariate analysis. In 
multivariate Cox regression analysis KPS score,
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Cranial progression free survival (weeks)
F ig .4 . :  Comparison of survival rates for patients with single
0  26 52 78 104 130 156
weeks
F ig .2 . :  Cranial progression free survival rate. F ig .5 . :  Comparison of survival rates due to Karnofsky 
Performance Scale scores.
F ig .3 . :  Comparison of overall survival rates for 
metastatectomy/radiosurgery + radiotherapy 
(M/S+RT) and radiotherapy alone (RT) groups.
F ig .6 . :  Survival rate curves due to absence (-) or presence 
(+) of distant métastasés other than brain.
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F i g . 7  •s Survival rate curves due to age distribution of <57 
vs. >57.
F i g . 8 . :  Comparison of survival rates due to gender.
T a b le  II. Prognostic factors analysed  In multivariate analysis 
(KPS: Karnofsky Perform ance  Scale)  (Statistically 
significant factors in bold).
p value
KPS score 0.0001
Gender 0.0328
Metastatectomy / Radiosurgery 0.0392
Age 0.3336
Solitary or multiple 0.3432
Other distant metastases 0.3788
gender and M/RS were found to be independent 
prognostic factors for overall survival (Table II).
D IS C U S S IO N
Patients with brain metastases is a very poor 
prognostic group of cancer patients. Our survival 
results coincide with published results of world 
series which show 3-6 months of median survival 
and 15% 1-year survival (6, 11, 12). The most 
important patient and disease related good 
prognostic factors such as younger age, higher 
performance status, single lesion, 
indisseminated disease other than brain found to 
be significant in univariate analysis are similar to 
findings in larger series (12, 13). Age and 
performance status remains significant in 
multivariate analysis.
The significance of M/RS in univariate analysis 
continues to be significant in multivariate 
analysis, furthermore terminating the significance 
of single or multiple lesions. In two randomized 
trials comparing surgery and radiotherapy to 
radiotherapy alone for patients with solitary brain 
metastases and inactive extra-cranial disease 
adding surgery significantly prolonged median 
survival (3.5vs. 9 months and 6 vs. 10 months) 
(1, 14). In our study group when a subgroup 
analysis is performed for solitary or multiple 
metastases, M/RS is still a prognostic factor. In 
the group with multiple metastases median and 1 
year survival results are 11 weeks and 9,6% for 
only radiotherapy patients, 65 weeks and 58,3% 
for M/RS + radiotherapy patients (p=0.01). 
Recent publications assessing the role of 
radiosurgery in the treatment of multiple brain 
metastases support our results (15, 16). In 
Chang et al.'s report it is concluded that 
radiosurgery for up to four brain metastases can 
be used with a 91% rate of response and 9.6 
months median survival (15).
In conclusion, external radiotherapy is an 
efficient treatment modality for palliation and 
stabilizing cranial progression in patients with 
brain metastases. Adding metastatectomy or 
radiosurgery to radiotherapy in young patients 
with good performance, less than four lesions 
and controlled systemic disease may reveal 
longer survival and cranial symptom 
control.
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